文献速递慢性肾脏病

慢性肾脏病中的便秘

Constipation in CKD.
PubMed 文献 · Kidney Int Rep · 2019-11-13

本文综述慢性肾脏病(CKD)患者便秘的诊断、患病率、病因、结局与治疗。便秘在CKD中常见且与生活质量下降、终末期肾病、心血管疾病和死亡独立相关,可能由肠道菌群改变和粪便代谢物增多介导。新型通便药物可能具有肾脏保护作用,但CKD便秘长期被低估且管理策略缺乏文献记录。

要点

  • CKD患者便秘常见,与不良临床结局独立相关。
  • 便秘可能通过肠道菌群改变和毒素蓄积影响CKD预后。
  • 新型通便药物可能提供额外肾脏保护获益。

核心结论

  • 便秘在CKD患者中常见且与终末期肾病、心血管疾病和死亡独立相关。
  • 便秘可能通过改变肠道菌群和增加粪便代谢物产生介导不良结局。
  • 新型通便药物可能具有独特肾脏保护特性,管理便秘或提供额外治疗获益。

研究设计与样本

  • 综述,总结CKD中便秘的诊断、患病率、病因、结局和治疗。

主要发现

  • 便秘负向影响生活质量并造成社会和经济负担。
  • 流行病学研究显示便秘与终末期肾病、心血管疾病和死亡独立相关。
  • 肠道在尿毒症毒素清除及酸碱和矿物质稳态中起重要作用,便秘可能限制这些功能。

临床怎么用

  • CKD患者应重视便秘的识别和管理,因其与不良结局相关。
  • 管理便秘可能超越常规排便控制,带来额外治疗获益。

局限性

  • CKD便秘长期被低估,管理策略文献记录稀少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Constipation is one of the most common gastrointestinal disorders among patients with chronic kidney disease (CKD) partly because of their sedentary lifestyle, low fiber and fluid intake, concomitant medications (e.g., phosphate binders), and multiple comorbidities (e.g., diabetes). Although constipation is usually perceived as a benign, often self-limited condition, recent evidence has challenged this most common perception of constipation. The chronic symptoms of constipation negatively affect patients' quality of life and impose a considerable social and economic burden. Furthermore, recent epidemiological studies have revealed that constipation is independently associated with adverse clinical outcomes, such as end-stage renal disease (ESRD), cardiovascular (CV) disease, and mortality, potentially mediated by the alteration of gut microbiota and the increased production of fecal metabolites. Given the importance of the gut in the disposal of uremic toxins and in acid-base and mineral homeostasis with declining kidney function, the presence of constipation in CKD may limit or even preclude these ancillary gastrointestinal roles, potentially contributing to excess morbidity and mortality. With the advent of new drug classes for constipation, some of which showing unique renoprotective properties, the adequate management of constipation in CKD may provide additional therapeutic benefits beyond its conventional defecation control. Nevertheless, the problem of constipation in CKD has long been underrecognized and its management strategies have scarcely been documented. This review outlines the current understanding of the diagnosis, prevalence, etiology, outcome, and treatment of constipation in CKD, and aims to discuss its novel clinical and therapeutic implications.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sumida K, Yamagata K, Kovesdy CP, et al. Constipation in CKD. Kidney Int Rep. 2019. PMID: 32043026. doi:10.1016/j.ekir.2019.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。